MedTrace Logo

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

NCT00884546 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2016-09-30

No results posted yet for this study

Summary

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.

Conditions

  • Advanced Cancer, Various, NOS

Interventions

DRUG

BMS-833923

Capsule, Oral, Once daily, 6 months

DRUG

Lenalidomide

Capsule, Oral, Once daily, 6 months

DRUG

Dexamethasone

Capsule, Oral, Once a week, 6 months

DRUG

Bortezomib

Powder, IV, On days 1, 4, 8, 11, 6 months

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884546 on ClinicalTrials.gov